Skip to Content

'
Patrick A. Zweidler-McKay, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Section Chief for Pediatric Leukemia and Lymphoma, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Bio Statement

My interests are in developing targeted therapies for children with leukemias and neuroblastoma and providing the latest therapies in a safe, family-centered environment.
         Clinically, I specialize in treating children with particularly difficult or relapsed forms of leukemia and lymphoma, such as infant ALL and T-cell leukemia/lymphoma. I help children get access to the latest Phase I therapies and provide hope and comfort regardless of the outcome.
         The research in my laboratory is directed at understanding the critical pathways that contribute to leukemia and neuroblastoma. We are developing a wide range of therapies targeting Notch, RET, TRK, energy production (glycolysis), metastasis and tumor vessel formation (CXCR4), etc. In collaboration we also target EGFR in neuroblastoma, Notch signaling in osteosarcoma and Ewing’s sarcoma, and we expand cord blood stem cells and natural killer cells for novel transplant approaches. Our successes have opened first-in-children studies here at M. D. Anderson Cancer Center.

UT Graduate School of Biomedical Sciences website:  http://gsbs.uth.tmc.edu/tutorial/zweidler-mckay.html

Education & Training

Degree-Granting Education

1997 Temple University, Philadelphia, PA, MD, Medicine
1997 Temple University, Philadelphia, PA, PHD, Molecular Biology/Genetics
1989 Swarthmore College, Swarthmore, PA, BA, Biology

Postgraduate Training

7/2003-6/2004 Senior Oncology Research Fellow, Children's Hospital of Philadelphia, Philadelphia, PA
7/2000-6/2003 Clinical Fellowship, Pediatric Hematology & Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
7/1997-6/2000 Clinical Fellow in Pediatrics, Harvard Medical School, Boston, MA
7/1997-6/2000 Clinical Residency, Pediatrics, Massachusetts General Hospital, Boston, MA

Board Certifications

11/2004 American Board of Pediatrics, Pediatric Hematology/Oncology
2000 American Board of Pediatrics

Experience/Service

Other Appointments/Responsibilities

Chair, Young Investigators Committee, Children's Oncology Group, Arcadia, CA, 1/2012-present
Member, Cancer Biology Program, University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2011-present
Member, ASPHO Program Committee, American Society of Pediatric Hematology Oncology, Glenview, IL, 2011-present
Local Study Chair, CA216002: Phase I Study of the NOTCH Inhibitor BMS-906024 in Relapsed T-cell Lymphoblastic Leukemia and Lymphoma, Bristol-Myers Squibb, Lawrenceville, NJ, 2011-present
Member, National Research Council Review Committee - IRIS Assessment on Formaldehyde and Leukemia, National Academies, Washington, DC, 2010-present
National Co-Chair, AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia, Children's Oncology Group, Arcadia, CA, 2010-present
Vice-Chair, Professional Development Committee, American Society of Pediatric Hematology and Oncology, Glenview, IL, 2010-present
Editorial Board Member, ISRN Hematology Journal, 2010-present
Member, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present
Pediatric Section Editor, CANCER, American Cancer Society Journal, Atlanta, GA, 2010-present
Board Member, Pfizer Hematology Advisory Board, New York, NY, 2010
National Vice Chair, ADVL0919: Phase I Study of RO4929097: A GSI for Relapsed Solid Tumors and T-ALL, Children's Oncology Group, Arcadia, CA, 2009-present
Local Study Chair, ADVLO4P2: Phase I/II Study of Epratuzumab for Relapsed ALL, NCT00098839, Children's Oncology Group, Arcadia, CA, 2008-present
Acute Lymphoblastic Leukemia Committee, Children's Oncology Group, Arcadia, CA, 2008-present
Member, Young Investigator's Committee, ALL Liaison, Children's Oncology Group, Arcadia, CA, 2008-present
ALL Molecular Risk Classifier Task Force, Children's Oncology Group, Arcadia, CA, 2008-2009
Hematologic Malignancies Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007-present
High Risk ALL Study Task Force, Children's Oncology Group, Arcadia, CA, 2007-2008

Institutional Committee Activities

Member, Faculty Mentoring Advisory Committee, 2008-present
Member, Children's Cancer Hospital Pediatric Support Care Committee, 2008-present
Member, American Cancer Society - Institutional Research Grant Committee, 2008-present
Member, Flow Cytometry & Cellular Imaging Core Facility Committee, 7/2007-present
Member, Institutional Research Grant Committee, 2005-2008

Honors and Awards

2005 Physician-Scientist Award, The University of Texas M.D. Anderson Cancer Center
2004 Young Investigator Travel Award, ASPHO
2003 Young Investigator Award, American Society of Pediatric Hematology & Oncology
2000 Excellence in Teaching Award, Cambridge Hospital
1988 Elected Associate Member, Sigma Xi, Honorary Scientific Research Society

Professional Memberships

American Medical Association Medical Student Section (AMA-MSS)
Judge, Resident and Fellow Section Research Symposium, 11/2009
American Society of Hematology, Washington, DC
Member, 2005-present
Children's Oncology Group, Arcadia, CA
Member, 2005-present
Harris County Medical Society, Houston, TX
Member, 2007-present
Texas Medical Society, Austin, TX
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Rabin KR, Gramatges MM, Borowitz MJ, Palla SL, Shi X, Margolin JF, Zweidler-McKay PA. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 59(3):468:74, 9/2012. e-Pub 11/18/2011. PMCID: PMC3290726.
2. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, JS Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R?null (NSG) mice. Exp Hematol 40(6):445-56, 7/2012. PMCID: PMC3352960.
3. Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay P. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatric Blood Cancer 58(5):682-9, 5/2012. PMCID: PMC3264695.
4. Blonska M, Joo D, Zweidler-McKay PA, Zhao Q, Lin X. CARMA1 Controls Th2 Cell-Specific Cytokine Expression through Regulating JunB and GATA3 Transcription Factors. J Immunol 188(7):3160-8, 4/1/2012. e-Pub 2/27/2012. PMCID: PMC3311756.
5. Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Zhang X, Vannini I, Fanini F, Fabbri M, Lanza G, Reis RM, Zweidler-McKay PA, Calin GA. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology 142(4):886-896, 4/2012. e-Pub 1/10/2012. PMCID: PMC3321100.
6. Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J, Zweidler-McKay PA. Notch/HES1-mediated PARP1 activation: a cell-type specific mechanism for tumor suppression. Blood 117(10):2891-2900, 3/10/2011. e-Pub 1/11/2011. PMCID: PMC3062299.
7. Zage PE, Graham TC, Zeng L, Fang W, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA. The Selective Trk Inhibitor AZ623 Inhibits BDNF-Mediated Neuroblastoma Cell Proliferation and Signaling and is Synergistic with Topotecan. Cancer 117(6):1321-91, 3/15/2011. e-Pub 10/19/2010. PMID: 20960503.
8. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother 33(7):684-96, 9/2010. PMCID: PMC3530422.
9. Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DP. Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth in vitro and in vivo. Cancer 116(13):3233-3243, 7/2010. PMCID: PMC2923448.
10. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: Implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29(20):2938-49, 5/20/2010. e-Pub 3/8/2010. PMID: 20208561.
11. Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA. A Novel Therapeutic Combination for Neuroblastoma: the VEGFR/EGFR/RET Inhibitor Vandetanib with 13-cis-Retinoic Acid. Cancer 116(10):2465-75, 5/2010. PMCID: PMC3264695.
12. Zhang P, Yang Y, Nolo R, Zweidler-McKay PA, Hughes DP. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex1 and its role in osteosarcoma invasiveness. Oncogene 20(29):2916-26, 5/2010. e-Pub 3/2010. PMCID: PMC2874642.
13. Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z, Zweidler-McKay P, Brandt SJ, Agulnick A, Nagarajan L. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene 29(21):3044-53, 5/2010. e-Pub 3/2010. PMCID: PMC2878399.
14. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 16(3):848-56, 2/2010. e-Pub 1/2010. PMCID: PMC2818539.
15. Steiner D, Gelovani J, Savoldo B, Robinson SN, Decker WK, Brouard N, Najjar A, Xing D, Yang H, Li S, Marini F, Zweidler-McKay PA, Bollard CM, Shpall EJ, Dotti G, Simmons PJ. Noninvasive Bioluminescent Imaging Demonstrates Long-Term Multilineage Engraftment of Ex Vivo-Expanded CD34-Selected Umbilical Cord Blood Cells. Stem Cells 27(8):1932-1940, 8/2009. PMID: 19544439.
16. Thress K, MacIntyre T, Wang H, Whiston D, Liu ZY, Hoffmann E, Want T, Brown JL, Webster K, Omer C, Zage PE, Zeng L, Zweidler-McKay PA (senior author). Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 8(7):1818-27, 7/2009. PMID: 19509272.
17. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA (senior author). Absolute lymphocyte count is a novel prognostic indicator in acute leukemia: Implications for risk stratification and future studies. Cancer 112(2):407-15, 2008. PMID: 18058809.
18. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of Notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 14(10):2962-9, 2008. PMCID: PMC2830718.
19. Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal Granulocyte-Macrophage Colony Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis. Antimicrob Agents Chemother 52(2):716-8, 2008. e-Pub 11/2007. PMCID: PMC2224773.
20. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-McKay P, Ryan A, Folkman J, Ryeom S, Heymach J. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7(2):418-24, 2008. e-Pub 2/2008. PMID: 18245671.
21. Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang YJ, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay P, Grupp SA. Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood 111(2):705-14, 2008. e-Pub 10/2007. PMCID: PMC2200835.
22. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC, Aster JC, Allman D, Pear WS. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B cell malignancies. Blood 106(12):3898-906, 2005. e-Pub 8/2005. PMCID: PMC1895093.
23. Zweidler-McKay PA, Grimes HL, Flubacher MM, Tsichlis PN. Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. Mol Cell Biol 16(8):4024-4034, 1996. PMCID: PMC231398.
24. Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN. The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by IL-2 withdrawal. Molecular and Cellular Biology 16(11):6263-6272, 1996. PMCID: PMC231629.
25. Bell DW, Taguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Gilks CB, Zweidler-McKay P, Grimes HL, Tsichlis PN, Testa JR. Chromosomal localization of a gene, GF1, encoding a novel zinc finger protein reveals a new syntenic region between man and rodents. Cytogenet Cell Genet 70(3-4):263-7, 1995. PMID: 7789186.
26. Cohen BH, Zweidler P, Goldwein JW, Molloy J, Packer RJ. Ototoxic effect of cisplatin in children with brain tumors. Pediatric Neurosurgery 16(6):292-296, 1990. PMID: 2134738.

Abstracts

1. Graham C, Darwin J, Zweidler-McKay P, Kannan S, Collins-Underwood R, Mullighan C. The Sun and the Sea: Balancing Ikaros in AML, T-ALL and B-ALL. Pediatric Blood & Cancer 56(6):923-923, 6/2011.
2. Sceusi E, Rasid A, Zhou Y, Samuel S, Fan F, Xia L, Ye X-C, Lu J, Tozzi F, Gaur P, Fleming JB, Abdalla ED, Curley SA, Vauthey J-N, Zweidler-McKay P, Meyn R, Yao J, Ellis LM. Primary culture of human midgut carcinoid cell lines and isolation of a putative carcinoid stem cell population. Presented at AACR 102nd Annual Meeting, 4/2011.
3. Sceusi E, Rashid A, Zhou YF, Samuel S, Fan F,Xia L, Ye XC, Lu J, Tozzi F, Gaur P, Zweidler-McKay P, Meyn R, Yao J, Ellis LM. Methods in the Development of Human Carcinoid Cell Lines. Pancreas 40(2):331-331, 3/2011.
4. Kannan S, Fang WD, Zweidler-McKay P. NOTCH and PLK1: Targeting Novel Mechanisms in B-ALL. Pediatric Blood & Cancer 56(6):922-922, 2011.
5. Zage P, Nolo R, Fang W, Zweidler-McKay P, Garcia-Manero G. Epigenetic Silencing of the Notch Signaling Pathway in Neuroblastoma Tumor Cells. Pediatric Blood & Cancer 55(5):893 (#PH025), 11/2010.
6. Hughes D, Zhang P, Yang Y, Katz D, Thomas D, Zweidler-McKay P. Notch Pathway Activity, Especially HES1, Drive Invasion and Metastasis in Osteosarcoma. Pediatric Blood & Cancer 55(5):830 (#0159), 11/2010.
7. Nolo R, Zage PE, Zweidler-McKay, PA. Epigenetic Silencing of the Notch Signaling Pathway in Neuroblastoma Tumor Cells. Presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP), Boston, MA (#485), 2010.
8. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Kornblau S, Zweider-McKay PA, Qui Y, Wilson W, Campana D, Borthakur G, Bueso-C, Kantarjian H, Shpall E, Thomas DA, Jordan C, Lock R, Andreeff, Konopleva M. Hypoxic Leukemic Microenvironment and its Targeting by the Hypoxia-activated Prodrug PR-104. Presented at the 2010 Hematologic Conference at UT MD Anderson Cancer Center in Houston, TX (#203), 2010.
9. Zweidler-McKay PA, Benjamin C, Wieder ED,Fang W, Fang W, Komanduri KV, Kim T. Insights into immune suppression during ALL induction therapy: Can CD4+ T cells save the day?. Presented at The 23rd Annual Meeting of the American Society of Pediatric Hematology & Oncology (#247), 2010.
10. Zweidler-McKay PA, Rabin KR, Borowitz MJ, S Palla, X Shi, Margolin J, Gramatges MM. Refining MRD-Based Risk Stratification in Pediatric ALL using Absolute Lymphocyte Counts. Presented at The 23rd Annual Meeting of the American Society of Pediatric Hematology & Oncology (#172), 2010.
11. Garcia-Manero G, Thomas D, Rytting M, Zweidler-McKay PA, Yang H, Fang Z, Kuang S, Dara S, O'Brien S, Kantarjian HM. A Phase 1 Study of Dose-Dense 5-Aza-2'-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocyte Leukemia (ALL). Blood, Presented at The 51st Annual Meeting of the American Society of Hematology 114(22):801-802 (#2030), 11/2009.
12. Kannan S and Zweidler-McKay PA. A Novel Cell-Specific Mechanism of Notch Signaling in Acute Lymphoblastic Leukemias - PARP1:HES1 Ratios. Poster Presentation at The 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009.
13. Levy AG, Nunnally LA, Zeng L, Fang W, Nolo R, Zage PE, Zweidler-McKay PA. A Novel in Vivo Role for CXCR4 Inhibition in Neuroblastoma. Oral Presentation at The 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009.
14. Rytting M, Thomas DA, Franklin AR, Zweidler-McKay PA, Jabbour E, Wierda W, Faderl S, Wells R, Kadia T, Ravandi F, Ferrajoli A, Cortes J, O'Brien S, Kantarjian H. Augmented Berlin-Frankfurt-Muenster Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Oral Presentation at The 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology (#139), 2009.
15. Kannan S, Zweidler-McKay PA. Cell Specific Consequences of Notch Signaling: PARP1/HES1 Interaction Reveals a Novel Tumor Suppressor Mechanism. Presented at The 51st Annual Meeting of the American Society of Hematology (#2388), 2009.
16. Robinson S, Yang H, Decker W, Xing D, Steiner D, Simmons P, Miller L, Cooper L, de Lima M, Champlin R, Shpall E, Zweidler-McKay P. Improved engraftment in an NOD-SCID IL-2Ry null mouse model following transplantation of fucosylated cord blood mononuclear cells. Presented at the ASBMT/CIBMTR 2009 BMT Tandem Meetings, 2009.
17. Levy AG, Akers LJ, Ghisoli ML, Graham TC, Zeng L, Nolo R, Zage PE, Fang W, Kannan S, Franklin AR, Huang P, Zweidler-McKay PA. Neuroblastoma and the Warburg Effect: The Novel Glycolysis Inhibitor 3-BrOP is Effective in Vitro and in Vivo. Oral Presentation at The 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009.
18. Nolo R, Fang W, Zage PE, Zweidler-McKay PA. Notch as a Tumor Suppressor in Neuroblastoma. Oral Presentation at The 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009.
19. Rytting M, Thomas DA, Franklin AR, Zweidler-McKay PA, Jabbour E, Wierda W, Faderl S, Wells R, Kadia T, Ravandi F, Ferrajoli A, Cortes J, O'Brien S, Kantarjian H. Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia. Presented at The 51st Annual Meeting of the American Society of Hematology (#2037), 2009.
20. Zhang P, Yang Y, Nolo R, Zweidler-McKay P, Hughes DPM. Regulation of Notch signaling by reciprocal inhibition of HES1 and Deltex1. Oral Presentation at the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009.
21. Ghisoli ML, Fang W, Levy AG, Graham TC, Nolo R, Kannan S, Pien C, Brown JL, Zweidler-McKay PA. Targeting TRKA: Preclinical Evaluation of AZ23 in Acute Myeloid Leukemia. Oral Presentation at The 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009.
22. Konopleva M, Benita J, Shi YX, Konoplev S, Kornblau SM, Frolova O, Zweidler-McKay PA, Qiu YH, Wilson WR, Campana D, Jacamo R, Lu H, Fang W, Borthakur G, Bueso-Ramos CE, Kantarjian HM, Thomas DA, Andreeff M. Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia. Presented at The 51st Annual Meeting of the American Society of Hematology (#2040), 2009.
23. Graham TC, Zeng L, Levy AG, Ghisoli ML, Kannan S, Nolo R, Fang W, Zage PE, Zweidler-McKay PA. TRKB in Neuroblastoma: Following Pathways to Better Therapies. Presented at The 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009.
24. Keck KN, Zage PE, Zweidler-McKay PA, Hughes DPM. Enhanced In Vivo Anti-Tumor Efficacy of Erlotinib for Neuroblastoma. Presented at the Advances in Neuroblastoma Research Conference, 5/2008.
25. Xing D, Fang W, Decker WK, Li S, Robinson SN, Yang H , Steiner D, Thomas MW, Champlin RE, McMannis JD, Shpall EJ, Zweidler-McKay PA. Ex Vivo Expansion of Cord Blood Nk Cells with In Vivo Efficacy Against Acute Myeloblastic and Lymphoblastic Leukemias. Presented at The 21st Annual Meeting of the American Society of Pediatric Hematology & Oncology, 4/2008.
26. Robinson SN, Yang H , Decker WK, Xing D, Steiner D, Ng J, Thomas MW, Champlin RE, Simmons PJ, Brouard N, Kidd S, Miler LP, Xia L, Cooper LJN, Shpall EJ, Zweidler-McKay PA. Ex Vivo Fucosylation of Cord Blood Cd34+ Stem Cells Improves the Rate and Magnitude of Engraftment. Presented at The American Society of Pediatric Hematology & Oncology 21st Annual Meeting, 4/2008.
27. Zeng L, Zage PE, Fang W, Nolo R, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA. Selective Trk inhibitor AZ623 effective against neuroblastoma in vitro and in vivo. Presented at the American Society of Pediatric Hematology & Oncology 21st Annual Meeting, 4/2008.
28. Keck KN, Zage PE, Zweidler-McKay PA, Hughes DPM. The ERBB family as a therapeutic target in neuroblastoma. Presented at the American Society of Pediatric Hematology & Oncology 21st Annual Meeting, 4/2008.
29. Levy AG, Akers LJ, Zeng L, Nolo R, Zage PE, Fang W, Kannan S, Franklin AR, Huang P, Zweidler-McKay PA. The glycolysis inhibitor 3-BrOP synergizes with rapamycin and is a novel therapeutic combination for neuroblastoma. Presented at the American Society of Pediatric Hematology & Oncology 21st Annual Meeting, 4/2008.
30. Akers LJ, Franklin AR, Fang W, Kannan S, Huang P, Zweidler-McKay PA. The novel glycolysis inhibitor, 3-BrOP, has broad activity against acute lymphoblastic leukemias (ALL) and synergizes with Rapamycin. Presented at 21st Annual Meeting of The American Society of Pediatric Hematology & Oncology, 4/2008.
31. Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA. A novel therapeutic combination for neuroblastoma: The VEGFR/EGF/RET inhibitor Vandetanib with 13-cis-Retinoic Acid. The 13th Advances in Neuroblastoma Research (ANR), 2008.
32. Levy AG, Sabella-River R, Ghisoli ML, Nunez CA, Anderson PM, Palla SL, De Angulo G, Zweidler-McKay PA. A Prognostic Role for Absolute Lymphocyte Counts in Pediatric Non-Hodgkin's Lymphoma. Presented at the American Society of Hematology 50th Annual Meeting and Exposition (#3756), 2008.
33. Kidd S, Brouard N, Cao K, Robinson SN, Thomas MW, Nguyen T, Zweidler-McKay PA, Shpall EJ, Simmons PJ. Co-culture with murine bone marrow vascular endotherlial cells greatly enhances CD34+ and colony-forming cell potential in ex-vivo expansion of cord blood progenitors. Presented at The 6th International Society for Stem Cell Research (ISSCR) Annual Meeting, 2008.
34. Kuang S, Zweidler-McKay P, Yang H, Fang ZH, Tong W, Garcia-Manero G. Epigenetic Inactivation of Notch Signaling Target Genes HES in B Cell Acute Lymphoblastic Leukemia. Presented at the American Society of Hematology 50th Annual Meeting and Exposition (#3372), 2008.
35. Xing D, Ramsay AG, Gribben JG, Decker WK, Burt JK, Li S, Simon SN, Yang H, Cooper L, McMannis JD, Champlin RE, Shpall EJ, Zweidler-McKay P, Bollard CM. Ex Vivo Expansion of Cord Blood NK Cells Overcomes Impaired Immune Synapse Formation and Effector F unction in Acute Myeloid Leukemia. Presented at the American Society of Hematology 50th Annual Meeting and Exposition (#2905), 2008.
36. Rytting M, Zweidler-McKay P, Hui Y, Kantarjian H, Garcia-Manero-G. Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia. American Society of Hematology 50th Annual Meeting and Exposition (#4036), 2008.
37. Zhang P, Mobley AK, Yang Y, Lee KA, Zweidler-McKay PA, Hughes DPM. Notch Signaling pathway contributes to osteosarcoma growth, tumorigenesis and metastasis. Presented at the American Association for Cancer Research 99th Annual Meeting (#2690), 2008.
38. Zhang P, Yang Y, Lee K, Zweidler-McKay P, Hughes DPM. Notch/HES1/DTX1 signaling controls osteosarcoma invasiveness and metastasis in vivo. Presented at the American Association for Cancer Research 99th Annual Meeting (#1984), 2008.
39. Mallampati S, Sun B, Gong Y, Wang E, You MJ, Amin HM, Ma Y, Shen H, Zweidler-McKay P, Jones D, Yin C, Glassman A, Kantarjin HM, Arlinghas RB, Sun X. Rooting into the Soil, a Model for the Role of Sox4 in Leukemia. Presented at the American Society of Hematology 50th Annual Meeting and Exposition (#3794), 2008.
40. Ghisoli M, Fang W, Kannan S, Zweidler-McKay P, Levy A, Pien C, Omer C, Thress K, Brown J. TRK inhibition may be a novel therapeutic option for selected group of acute myeloblastic leukemias. Presented at The 40th Congress of the International Society of Paediatric Oncology (SIOP) (#627), 2008.
41. Ghisoli ML, Fang W, Graham TC, Levy AG, Zeng L, Kannan S, Nolo RM, Pien C, Brown JL, Zweidler-McKay PA. Understanding the Role of TRKA Receptor in Acute Myeloid Leukemias: From Proliferation and Pro-Survival Signals to a Novel Therapeutic Approach. Presented at the American Society of Hematology 50th Annual Meeting and Exposition (#3789), 2008.
42. Steiner D, Robinson SN, Decker WK, Xing D, Yang H, Marini FC, Shpall EJ, McMannis JD, Cooper L, Gelovani JG, Najjar AM, De Stasi A, Quintarelli C, Zweidler-McKay PA, Dotti G. A small animal in vivo imaging model of expanded vs. unexpanded UCB stem cells reveals differential patterns of engraftment. Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
43. Robinson SN, de Lima M, Yang H, Decker WK, Xing D, Steiner D, Ng J, Thomas MW, Champlin RE, Hosing CM, Simmons PJ, Brouard N, Kidd S, Cooper L, Zweidler-McKay PA, Shpall EJ. Cobblestone area-forming cell (CAFC) content of cord blood does not predict engraftment in double cord blood transplantation. Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
44. Xing D, Li S, Robinson S, Decker W, Steiner D, Yang H, Thomas M, Champlin RE, McMannis JD, Vina MF, Cooper LJN, Simmons PJ, Zweidler-McKay PA, Shpall EJ. Cord Blood NK Cytotoxic Activity can be Selectively-modulated by Accessory Cells. Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
45. Robinson SN, Simmons PJ, Brouard N, Kidd S, Yang H, Decker WK, Xing D, Steiner D, Ng J, Thomas MW, Champlin RE, de Lima M, Hosing CM, Cooper LJ, Sing H, Zweidler-McKay PA, Shpall EJ. Efficacy of "Off-the-Shelf", commercially-available, third-party Mesenchymal Stem Cells (MSC) in ex vivo Cord Blood (CB) co-culture expansion. Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
46. Xing D, Fang W, Decker WK, Li S, Robinson SN, Yang H, Steiner D, Thomas M, Champlin RE, McMannis JD, Shpall EJ, Zweidler-McKay PA (senior author). Ex Vivo Expansion of Cord Blood NK Cells have in vivo Efficacy Against Leukemia. Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
47. Robinson SN, Yang H, Decker WK, Xing D, Steiner D, Ng J, Thomas MW, Champlin RE, Simmons PJ, Brouard N, Kidd S, Cooper LJ, McMannis JD, Shpall EJ, Zweidler-McKay PA (senior author). Fucosylation of cord blood CD34+ cells improves the rate of engraftment without compromising long-term engraftment. Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
48. Kidd S, Brouard N, Cao K, Robinson SN, Thomas MW, Nguyen T, Thall PF, Qiao W, Zweidler-McKay PA, Shpall EJ, Simmons PJ. Manipulation of Oxygen Tension and Medium Composition to Enhance CD34+ Cell Numbers and Megakaryocytic Potential of Cord Blood Progenitors. Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
49. Garcia-Manero G, Thomas D, Rytting M, Zweidler-McKay PA, Estrov Z, Brown DL, O'Brien S, Yang H, Kantarjian H. Phase I study of 5-aza-2'-deoxycitidine, alone or in combination with hyper-CVAD, in relapsed or refractory acute lymphocytic leukemia (ALL). Presented at the American Society of Hematology 49th Annual Meeting and Exposition, 12/2007.
50. Akers LJ, Franklin AR, Huang P, Zweidler-McKay PA (senior author). The novel glycolysis inhibitor, 3-BrOP, has broad activity against acute lymphoblastic leukemias and potentiates methotrexate and rapamycin. Presented at the American Society of Hematology & Oncology 49th Annual Meeting and Exposition, 12/2007.
51. Sutphin RM, Fang W, Zweidler-McKay PA (senior author). Notch Agonists are a Potential Therapeutic Approach in pre-B ALL and AML. FASEB Hematopoietic Malignancies Summer Research Conference, 7/2007.
52. Hughes DP, Zhang P, Yang Y, Lee KE, Zweidler-McKay PA (senior author). Dominant negative HES1 blocks osteosarcoma invasion driven by Notch pathway signaling. Journal of Clinical Oncology, 2007 American Society of Clinical Oncology Annual Meeting Proceedings Part I 25(18S) (#9549), 6/2007.
53. Yang H, Thomas DA, Rytting ME, Zweidler-McKay PA, Brown DL, Kantarjian H, Garcia-Manero G. Phase I study of frequent low-dose administration of decitabine, alone or in combination with hyperCVAD, in relapsed or refractory acute lymphocytic leukemia (ALL). Journal of Clinical Oncology, 2007 American Society of Clinical Oncology Annual Meeting Proceedings Part I 25(18S) (#7072), 6/2007.
54. Zeng L, Nilsson MB, Heymach JV, Zage PE, Zweidler-McKay PA (senior author). A novel therapeutic combination for neuroblastoma: The RET inhibitor ZD6474 with cis-retinoic acid. Presented at the 20th Annual Meeting of The American Society of Pediatric Hematology & Oncology, 5/2007.
55. Levy AG, Ghisoli ML, Sabella-River R, DeAngulo GR, Palla SM, Nunez CA, Anderson PM, Zweidler-McKay PA (senior author). Absolute lymphocyte count predicts outcome in pediatric patients with non-Hodgkins lymphoma. Presented at the 20th Annual Meeting of The American Society of Pediatric Hematology & Oncology, 5/2007.
56. Sutphin RM, Fang W, MIller C, Campbell M, Zweidler-McKay PA (senior author). Development of Notch agonists for the treatment of pediatric AML. Presented at the 20th Annual Meeting of The American Society of Pediatric Hematology & Oncology (selected for Platform Oral Presentation), 5/2007.
57. Zhang P, Yang Y, Lee KE, Zweidler-McKay PA, Hughes DPM. HES1 expression, driven by notch signaling, is essential for osteosarcoma invasion. Presented at the 20th Annual Meeting of The American Society of Pediatric Hematology & Oncology (selected for Platform Oral Presentation-Invited Talk), 5/2007.
58. Akers L, Franklin A, Fang W, Huang P, Zweidler-McKay PA (senior author). The novel glycolysis inhibitor, 3-BrOP, offers a potential therapeutic approach in ALL and AML. Presented at The 20th Annual Meeting of the American Society of Pediatric Hematology & Oncology, 5/2007.
59. Nilsson MB, Wu H, Zeng L, Zage P, Zweidler-McKay P, Heymach JV. Sunitinib and sorafenib exert direct effects on neuroblastoma cells and inhibit hypoxia-induced increases in HIF-1a and VEGF. Presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR), 4/2007.
60. Levy AG, Sabella-River R, Ghisoli ML, DeAngulo GR, Palla SM, Nunez CA, Anderson PM, Zweidler-McKay PA (senior author). Absolute lymphocyte count predicts outcome in pediatric patients with non-Hodgkins lymphoma. Presented at the International Society of Paediatric Oncology (SIOP) 39th Annual Meeting, Mumbai, India, 2007.
61. Zhang P, Yang Y, Lee K, Zweidler-McKay P, Hughes DPM. HES1 and Deltex1: Yin and Yang controlling invasiveness and metastasis in osteosarcoma. Presented at the American Association for Cancer Research 98th Annual Meeting (#3943), 2007.
62. Zhang P, Yang Y, Lee KE, Zweidler-McKay P, Hughes DPM. HES1 expression, driven by notch signaling, is essential for osteosarcoma invasion. Presented at the Pediatric Academic Societies' Annual Meeting (#5292.2), 2007.
63. Zhang P, Yang Y, Lee K, Zweidler-McKay P, Hughes DPM. Notch activated transcription factor HES1: A master gene controlling invasiveness and metastasis of osteosarcoma. 7th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association Special Meeting: In the Forefront of Basic and Translational Cancer Research (poster presentation), 2007.
64. Zhang P, Yang Y, Lee K, Zweidler-McKay P, Hughes DPM. Notch activated transcription factor HES1: A master gene controlling invasiveness and metastasis of osteosarcoma. Presented at the Keystone Symposia on Molecular and Cellular Biology, Targets for Cancer (X3) (#372), 2007.
65. Zhang P, Yang Y, Lee K, Zweidler-McKay PA, Hughes DPM. Notch regulated HES1 controls tumor cell invasion and metastatic potential in osteosarcoma. Presented at the Connective Tissue Oncology Society 13th Annual Meeting, Seattle, WA, USA, 2007.
66. Hughes DPM, Zhang P, Thomas DG, Coombes KR, Yang Y, Zweidler-McKay PA (senior author). Notch-mediated expression of HES1 is essential for osteosarcoma metastasis. Presented at the Connective Tissue Oncology Society 13th Annual Meeting (#918), 2007.
67. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA (senior author). Absolute Lymphocyte Count is a Novel Prognostic Indicator in Acute Leukemia: Implications for Risk Stratification and Future Studies. Blood, American Society of Hematology 48th Annual Meeting (Poster Sessions) 108(11) (#2276), 11/2006.
68. Sutphin RM, Fang W, Miller C, Zweidler-McKay PA (senior author). Notch Agonists: Emerging as a Feasible Therapeutic Approach in AML. Blood, American Society of Hematology 48th Annual Meeting (Poster Sessions) 108(11) (#1419), 11/2006.
69. Tabe Y, Jin L, McQueen T, Andreeff M, Zweidler-McKay PA, Konopleva M. Notch1 signaling promotes survival of leukemic cells in close contact with bone marrow-derived stromal cells by activating AKT and Stat-3 pathways. Blood, American Society of Hematology 48th Annual Meeting (Poster Sessions) 108(11) (#1398), 11/2006.
70. Sutphin RM, Fang W, Zweidler-McKay PA (senior author). Notch Signaling: A Potential Therapeutic Target in AML. 19th Annual Meeting of The American Society of Pediatric Hematology & Oncology (selected for Platform Oral Presentation), 5/2006.
71. Zhang P, Mobley AK, Yang Y, Lee K, Zweidler-McKay PA, Hughes DP. Notch Signaling pathway contributes to osteosarcoma growth, tumorigenesis and metastasis. Presented at the 2006 Annual Meeting of The American Society of Clinical Oncology (ASCO), 5/2006.
72. Zhang P, Mobley AK, Yang Y, Lee K, Zweidler-McKay P, Hughes DPM. Notch signaling pathway plays a role in the cell survival and proliferation of osteosarcoma and y-secretase inhibitor can suppress the tumorigenesis of osteosarcoma cell in vitro. Presented at The 97th Annual Meeting of the American Association for Cancer Research (AACR), 2006.
73. Zweidler-McKay PA, Lum JJ, Thompson CB, Pear WS. A Critical Role for the Bcl-2 Pathway in Notch-Mediated B Cell Apoptosis, Where Growth Arrest is independent of the E2A, IL-3 and p21Waf1/p27Kip1 Pathways. Blood, American Society of Hematology 47th Annual Meeting (Oral Sessions) 106(237) (#237), 11/2005.
74. Zweidler-McKay PA, Grimes HL, Gilks CB, Tsichlis PN. Gfi-1 encodes a zinc finger protein which is localized in the nucleus and binds a specific DNA sequence. 9th Annual Meeting on Oncogenes. Foundation of Advanced Cancer Studies. (Poster & Abstract), 2005.
75. Zweidler-McKay PA. Notch as a Tumor Suppressor in B-ALL, Hematologic Malignancies Summer Research Conference. Federation of American Societies for Experimental Biology (FASEB), 2005.
76. Zweidler-McKay P, He Y, Xu L, Pear WS. Notch signaling induces growth inhibition and apoptosis in a wide range of human B cell leukemias. American Society of Pediatric Hematology & Oncology (selected for Platform Presentation, Young Investigator Travel Award), 2004.
77. Zweidler-McKay Patrick, Xu L, Pear WS. Notch signaling in human B cell leukemias induces apoptosis and cell death. American Society of Pediatric Hematology & Oncology (Young Investigator Award & Presentation), 2003.
78. Zweidler-McKay PA, Grimes HL, Tsichlis PN. Gfi-1 encodes a zinc finger protein which is localized in the nucleus, binds a specific DNA sequence and functions as a transcriptional repressor. 6th Workshop, Pathogenesis of Animal Retroviruses. (Poster & Abstract), 1994.

Grant & Contract Support

Title: Notch in Neuroblastoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2012
 
Title: HES1 mediates cell-specific consequences of Notch signaling in ALL
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2010 - 3/31/2015
 
Title: Analysis of histone code alterations and the role of histone demethylase JMJD3 using CHIP-seq in myelodysplastic syndrome
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: Garcia-Manero
Duration: 3/1/2010 - 2/28/2014
 
Title: Notch ligand peptides as a novel therapeutic approach in B-ALL and AML
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2008 - 9/30/2012

Last updated: 8/29/2013